Related Experiment Video
Updated: Jul 6, 2026

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells
Published on: October 27, 2009
Platelet aggregation and recruitment with aspirin-clopidogrel therapy
Cathy M Helgason1, Enzo Grossi, Dilip Pandey
1Department of Neurology, University of Illinois College of Medicine at Chicago, Chicago, IL 60612, USA. helgason@uic.edu
Insights
Aspirin-clopidogrel therapy enhances platelet inhibition over time in stroke patients. This combination therapy significantly reduces platelet aggregation and recruitment, suggesting improved antiplatelet effects with continued use.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Neurology
Background:
- Aspirin-clopidogrel combination therapy is known to inhibit platelet aggregation.
- The impact of this combination on platelet recruitment remains unclear.
Purpose of the Study:
- To investigate the effect of aspirin-clopidogrel combination therapy on platelet recruitment.
- To compare platelet reactivity between aspirin monotherapy and combination therapy in chronic ischemic stroke patients.
Main Methods:
- Platelet reactivity tests, including ex vivo platelet aggregation and recruitment, were performed on 30 patients over 3 months.
- Urinary 11-dehydro-thromboxane B(2) (11-dhTxB(2)) excretion was measured.
- Statistical analysis, including ANOVA and longitudinal regression, was used to compare outcomes and assess changes over time. Nonlinear mapping was employed to analyze patient-specific variable interconnections.
Main Results:
- Aspirin-clopidogrel significantly reduced adenosine-diphosphate- and collagen-induced platelet aggregation and platelet recruitment compared to aspirin alone.
- A time-dependent increase in the inhibition of platelet recruitment was observed with combination therapy.
- Urinary 11-dhTxB(2) levels did not correlate with platelet aggregation response. Patient-specific interconnections were revealed by nonlinear mapping.
Conclusions:
- Aspirin-clopidogrel combination therapy demonstrates increasing platelet inhibition over time.
- Further research is warranted to explore the clinical implications of this enhanced antiplatelet effect on vascular complications.
Background:
Aspirin-clopidogrel combination therapy inhibits platelet aggregation. The effect on platelet recruitment is unknown.
Methods:
Thirty chronic ischemic stroke patients taking aspirin alone followed by aspirin-clopidogrel combined therapy had platelet reactivity tests performed over 3 months: ex vivo platelet aggregation, platelet recruitment and urinary 11-dehydro-thromboxane B(2) (11-dhTxB(2))excretion. Statistical analysis of variance compared platelet aggregation and recruitment between aspirin alone and aspirin-clopidogrel, and longitudinal regression analysis estimated platelet recruitment over time. Nonlinear mapping defined variable connections in each patient.
Results:
Statistically significant differences were found between aspirin alone and aspirin-clopidogrel for (1) adenosine-diphosphate- and collagen-induced platelet aggregation and maximum inhibition of platelet recruitment and (2) increasing inhibition of platelet recruitment over time. Urinary 11-dhTxB(2) excretion did not predict platelet aggregation response. Nonlinear mapping showed patient-unique variable interconnections.
Conclusions:
Platelet inhibition with aspirin-clopidogrel may increase over time, and future studies should focus on this finding in the context of vascular complications.
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care

